TMDX

TransMedics Group, Inc. (TMDX) | Rumor.io

TransMedics Group

TMDX

Attention (50-day avg)0.01%

Attention rank (50-day avg)#550

Bullish sentiment (50-day avg)94%

Price to earnings ratio21.4

Market capitalization2.9B

Earnings per share3.86

Dividend yield (TTM)—

Revenue (annual)605.5M

Net income (annual)190.3M

Social

What share of all stock conversation is about TMDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0	0% -0.01	0.02% -0.07

Aug 31

TransMedics Group, Inc. (TMDX) has grossed an estimated $1,088,000 in the last 24 hours and is on track to do 2,786 flights and gross $189,448,000 this quarter.
TMDX will present at upcoming investor conferences, including the Morgan Stanley 24th Annual Global Healthcare Conference and the Baird 2026 Global Healthcare Conference.
TMDX's stock price is currently bearish, with a price of $82.91 (-9.63%) and a trend of bearish, but the market bias is bullish.

Generated by AI

Sentiment

Of the messages about TMDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% 0	96.26% +12.08	86.34% -3.44
Bearish	0% 0	0% 0	3.74% -12.08	13.66% +3.44

Bullish· Aug 10

* TransMedics Group, Inc. (TMDX) has broken major resistance, confirming a breakout, and is expected to retest new support levels.
* The 20-day MA has crossed above the 50-day MA, indicating a short-term momentum shift, with the target set on the next resistance band.
* TMDX is experiencing a bullish divergence on MACD vs price, suggesting sustained upside if volume holds, and is also seeing on-balance volume climb with price, confirming money flow into the stock.

Bearish· Aug 5

$TMDX's Q2 earnings beat was overshadowed by CEO's inability to explain product vs. services revenue growth, raising concerns about the company's strategy.
The stock's decline after the earnings call was exacerbated by the CEO's contradictory statements and a lack of clear vision for the company's future.
Analysts and investors are losing confidence in $TMDX, with downgrades and price target cuts, and some even labeling the CEO a "snake oil salesman" who can't be trusted.

Generated by AI

Topics

Of the messages about TMDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	61.74%	68.9%	21.75%
Earnings	—	18.26%	8.13%	17.33%
Analysts	—	9.57%	5.65%	24.13%
Technical Analysis	—	0.87%	13.43%	4.95%
Controversies	—	0%	0%	0.06%
Macro	—	9.57%	3.89%	31.77%

Earnings· Aug 4

TransMedics Group, Inc. reported Q2 2026 earnings with revenue of $189.9M, beating estimates by 3% and raising the full-year guidance to $737M-$757M.
The company's non-GAAP EPS of $0.44 missed estimates by 8%, but EPS improved 47% quarter over quarter and revenue grew 21% year over year.
The market reacted positively to the report, with shares increasing by 8.1%, and the CEO highlighted a record quarter driven by accelerating service growth, improving operational execution, and continued investment in long-term growth initiatives.

Analysts· Jun 21

Stifel raised its price target for TransMedics Group, Inc. (TMDX) to $80 from $75, citing strong flight data.
The firm expects TransMedics to report a solid second-quarter 2026 revenue beat of $195 million versus the Street's $183 million estimate.
Stifel maintains a Hold rating for TransMedics, despite the increased price target.

Announcements· Aug 4

TransMedics Group, Inc. (TMDX) reported Q2 2026 earnings, with revenue reaching $189.9M, a 21% YoY increase and a beat of $184M estimates.
The company raised its full-year guidance to $737M-$757M, from $733M estimates, and achieved a record revenue quarter driven by accelerating service growth and improving operational execution.
Despite a 52% drop in net income YoY, TransMedics' CEO highlighted a defining quarter for the company, with a focus on long-term growth initiatives and a solid report that rewards companies growing while improving profitability.

Technical Analysis· Oct 30

$TMDX has shown strong price action after its quarterly report, with a breakout retest and potential target prices of $145, $165, and $175.
The stock has held key technical levels, including the island reversal and trendline support, and is expected to continue moving higher after a solid earnings report and CEO share purchase.
$TMDX has demonstrated a classic shakeout and bounce pattern, with a strong risk-reward ratio and potential for further upside after a beautiful earnings report.

Generated by AI

Community

Of the messages about TMDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	89.66%	82.91%	88.71%	77.13%
Newcomers	10.34%	17.09%	11.29%	22.87%

Regulars· Aug 19

The stock has filled the gap from Q1 earnings, with a +58% increase from the lows, making it a successful addition to those who stayed patient and added during the pullback.
The company's core product, the OCS (Organ Care System), is a key part of its business, and its ability to perform well and stick to current timelines is crucial for the stock's future performance.
The stock needs to close above $93.18 to reach its next resistance and potentially run up to $100, and it's essential to hold the current price of $93.19 or better to continue running higher.

Newcomers· Aug 25

New investors are highlighting the risks of leverage and margin calls, with one user mentioning a potential 10% drop could trigger a loss of 1/3 of their portfolio.
The users are concerned about their portfolio's exposure, with one user stating they have a "3.3x leveraged portfolio" and another mentioning a situation where a 10% drop would be devastating.
The newcomer investors are asking for advice on managing their portfolios, with one user seeking guidance on how to proceed after losing nearly $200,000 in penny stocks.

Generated by AI

News

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too? | The Motley Fool

Weill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year.

20h agoThe Motley Fool

TransMedics Offers Attractive Entry Point, With Upside Potential Outweighing Risks (TMDX)

TransMedics is a market-changing player in organ transplant technology, with a unique multi-organ perfusion platform. Read more on TMDX stock here.

4d agoSeeking Alpha

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)

Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

TransMedics Stock: Waiting On 2027 Catalysts (NASDAQ:TMDX)

12d agoSeeking Alpha

2 Stocks Down 28% and 34% to Buy and Hold | The Motley Fool

These companies' sell-offs may have gone too far.

14d agoThe Motley Fool

TransMedics at 2026 Global Healthcare Conference: growth plan widens

14d agoInvesting.com

Also Discussed

Investors talking about TMDX also mention

#	Name	Attention
1	DMTK - DermTech, Inc.	——
2	Aspen Aerogels IncASPN	0%0
3	PROCEPT BioRobotics Corp.PRCT	0%0
4	Celsius Holdings IncCELH	0.01%-0.06
5	SWAV - ShockWave Medical, Inc.	——
6	dLocal LimitedDLO	0%new
7	Shift4 Payments Inc. Class A Common StockFOUR	0%new
8	NARI - Inari Medical, Inc.	——
9	ClearPoint Neuro Inc.CLPT	0.03%+0.02
10	Oscar Health, Inc.OSCR	0.05%+0.02

TransMedics Group, Inc.

Healthcare
Medical Devices

TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy. The company develops and commercializes the Organ Care System (OCS), a platform designed to preserve, monitor, and assess donor organs outside the human body in conditions that more closely resemble a living environment. Its current portfolio supports heart, lung, and liver transplantation, helping transplant teams manage donor organs more effectively than traditional cold storage methods. TransMedics also provides related disposables and service offerings that support organ transport, preservation, and clinical workflow in the transplant process. Headquartered in Andover, Massachusetts, TransMedics Group, Inc. serves a specialized role in healthcare by addressing the needs of patients with end-stage organ failure and supporting hospitals, transplant centers, and organ recovery organizations across its markets.

Website

Location

200 Minuteman Road

Andover, MA, 01810

United States

Social

What share of all stock conversation is about TMDX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0	0% -0.01	0.02% -0.07

Aug 31

TransMedics Group, Inc. (TMDX) has grossed an estimated $1,088,000 in the last 24 hours and is on track to do 2,786 flights and gross $189,448,000 this quarter.
TMDX will present at upcoming investor conferences, including the Morgan Stanley 24th Annual Global Healthcare Conference and the Baird 2026 Global Healthcare Conference.
TMDX's stock price is currently bearish, with a price of $82.91 (-9.63%) and a trend of bearish, but the market bias is bullish.

Generated by AI

Sentiment

Of the messages about TMDX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% 0	96.26% +12.08	86.34% -3.44
Bearish	0% 0	0% 0	3.74% -12.08	13.66% +3.44

Bullish· Aug 10

* TransMedics Group, Inc. (TMDX) has broken major resistance, confirming a breakout, and is expected to retest new support levels.
* The 20-day MA has crossed above the 50-day MA, indicating a short-term momentum shift, with the target set on the next resistance band.
* TMDX is experiencing a bullish divergence on MACD vs price, suggesting sustained upside if volume holds, and is also seeing on-balance volume climb with price, confirming money flow into the stock.

Bearish· Aug 5

$TMDX's Q2 earnings beat was overshadowed by CEO's inability to explain product vs. services revenue growth, raising concerns about the company's strategy.
The stock's decline after the earnings call was exacerbated by the CEO's contradictory statements and a lack of clear vision for the company's future.
Analysts and investors are losing confidence in $TMDX, with downgrades and price target cuts, and some even labeling the CEO a "snake oil salesman" who can't be trusted.

Generated by AI

Topics

Of the messages about TMDX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	61.74%	68.9%	21.75%
Earnings	—	18.26%	8.13%	17.33%
Analysts	—	9.57%	5.65%	24.13%
Technical Analysis	—	0.87%	13.43%	4.95%
Controversies	—	0%	0%	0.06%
Macro	—	9.57%	3.89%	31.77%

Earnings· Aug 4

TransMedics Group, Inc. reported Q2 2026 earnings with revenue of $189.9M, beating estimates by 3% and raising the full-year guidance to $737M-$757M.
The company's non-GAAP EPS of $0.44 missed estimates by 8%, but EPS improved 47% quarter over quarter and revenue grew 21% year over year.
The market reacted positively to the report, with shares increasing by 8.1%, and the CEO highlighted a record quarter driven by accelerating service growth, improving operational execution, and continued investment in long-term growth initiatives.

Analysts· Jun 21

Stifel raised its price target for TransMedics Group, Inc. (TMDX) to $80 from $75, citing strong flight data.
The firm expects TransMedics to report a solid second-quarter 2026 revenue beat of $195 million versus the Street's $183 million estimate.
Stifel maintains a Hold rating for TransMedics, despite the increased price target.

Announcements· Aug 4

TransMedics Group, Inc. (TMDX) reported Q2 2026 earnings, with revenue reaching $189.9M, a 21% YoY increase and a beat of $184M estimates.
The company raised its full-year guidance to $737M-$757M, from $733M estimates, and achieved a record revenue quarter driven by accelerating service growth and improving operational execution.
Despite a 52% drop in net income YoY, TransMedics' CEO highlighted a defining quarter for the company, with a focus on long-term growth initiatives and a solid report that rewards companies growing while improving profitability.

Technical Analysis· Oct 30

$TMDX has shown strong price action after its quarterly report, with a breakout retest and potential target prices of $145, $165, and $175.
The stock has held key technical levels, including the island reversal and trendline support, and is expected to continue moving higher after a solid earnings report and CEO share purchase.
$TMDX has demonstrated a classic shakeout and bounce pattern, with a strong risk-reward ratio and potential for further upside after a beautiful earnings report.

Generated by AI

Community

Of the messages about TMDX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	89.66%	82.91%	88.71%	77.13%
Newcomers	10.34%	17.09%	11.29%	22.87%

Regulars· Aug 19

The stock has filled the gap from Q1 earnings, with a +58% increase from the lows, making it a successful addition to those who stayed patient and added during the pullback.
The company's core product, the OCS (Organ Care System), is a key part of its business, and its ability to perform well and stick to current timelines is crucial for the stock's future performance.
The stock needs to close above $93.18 to reach its next resistance and potentially run up to $100, and it's essential to hold the current price of $93.19 or better to continue running higher.

Newcomers· Aug 25

New investors are highlighting the risks of leverage and margin calls, with one user mentioning a potential 10% drop could trigger a loss of 1/3 of their portfolio.
The users are concerned about their portfolio's exposure, with one user stating they have a "3.3x leveraged portfolio" and another mentioning a situation where a 10% drop would be devastating.
The newcomer investors are asking for advice on managing their portfolios, with one user seeking guidance on how to proceed after losing nearly $200,000 in penny stocks.

Generated by AI

TransMedics Group

Social

Aug 31

Bullish· Aug 10

Bearish· Aug 5

Earnings· Aug 4

Analysts· Jun 21

Announcements· Aug 4

Technical Analysis· Oct 30

Regulars· Aug 19

Newcomers· Aug 25

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too? | The Motley Fool

TransMedics Offers Attractive Entry Point, With Upside Potential Outweighing Risks (TMDX)

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)

TransMedics Stock: Waiting On 2027 Catalysts (NASDAQ:TMDX)

2 Stocks Down 28% and 34% to Buy and Hold | The Motley Fool

TransMedics at 2026 Global Healthcare Conference: growth plan widens

Also Discussed

TransMedics Group, Inc.

Company Information

Location

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too? | The Motley Fool

TransMedics Offers Attractive Entry Point, With Upside Potential Outweighing Risks (TMDX)

Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)

TransMedics Stock: Waiting On 2027 Catalysts (NASDAQ:TMDX)

2 Stocks Down 28% and 34% to Buy and Hold | The Motley Fool

TransMedics at 2026 Global Healthcare Conference: growth plan widens

Also Discussed

Social

Aug 31

Bullish· Aug 10

Bearish· Aug 5

Earnings· Aug 4

Analysts· Jun 21

Announcements· Aug 4

Technical Analysis· Oct 30

Regulars· Aug 19

Newcomers· Aug 25